188 related articles for article (PubMed ID: 28315558)
1. Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm
.
Mistry H; Forbes SG; Fowler N
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):53-59. PubMed ID: 28315558
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management
.
Gordon R; Kasler MK; Stasi K; Shames Y; Errante M; Ciccolini K; Skripnik Lucas A; Raasch P; Fischer-Cartlidge E
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):45-52. PubMed ID: 28315555
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy Toxicities.
Sanchez K; Page DB; Urba W
Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
[TBL] [Abstract][Full Text] [Related]
4. Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice.
Bayer V; Amaya B; Baniewicz D; Callahan C; Marsh L; McCoy AS
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):13-21. PubMed ID: 28315552
[TBL] [Abstract][Full Text] [Related]
5. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Administration: Oncology Nursing Society Recommendations
.
Wiley K; LeFebvre KB; Wall L; Baldwin-Medsker A; Nguyen K; Marsh L; Baniewicz D
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):5-7. PubMed ID: 28315551
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy Summit: Proceedings and Identified Priorities for Safe Administration and Care.
Galioto M; Mucenski J
Clin J Oncol Nurs; 2019 Jun; 23(3):E60-E65. PubMed ID: 31099794
[TBL] [Abstract][Full Text] [Related]
8. The Future of Immunotherapy in the Treatment of Cancer.
Kottschade LA
Semin Oncol Nurs; 2019 Oct; 35(5):150934. PubMed ID: 31477413
[TBL] [Abstract][Full Text] [Related]
9. Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma.
Ugolini H; Bryan J; Hennessy M; Kaufman HL; D'Angelo S
Clin J Oncol Nurs; 2019 Feb; 23(1):E1-E9. PubMed ID: 30682006
[TBL] [Abstract][Full Text] [Related]
10. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.
Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM
Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440
[TBL] [Abstract][Full Text] [Related]
11. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
Davies M
Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
[TBL] [Abstract][Full Text] [Related]
12. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
13. Immune-Mediated Therapies in Lymphoma.
Forbes SG; Mistry HE
Semin Oncol Nurs; 2019 Oct; 35(5):150925. PubMed ID: 31526549
[TBL] [Abstract][Full Text] [Related]
14. Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician.
Lomax AJ; McNeil C
Emerg Med Australas; 2017 Apr; 29(2):245-251. PubMed ID: 28093870
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F; Sykiotis GP; Maillard M; Fraga M; Ribi C; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Lancet Oncol; 2019 Jan; 20(1):e54-e64. PubMed ID: 30614479
[TBL] [Abstract][Full Text] [Related]
16. Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.
Socinski MA
Semin Oncol; 2015 Oct; 42 Suppl 2():S19-28. PubMed ID: 26477471
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy Toxicities:
A New Electronic Documentation Template to Improve Patient Care.
Reimschissel E; Dela Cruz B; Gonzalez M; Buitrago J; Goodman C; Johnston PA
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):41-44. PubMed ID: 28315559
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.
Eigentler TK; Hassel JC; Berking C; Aberle J; Bachmann O; Grünwald V; Kähler KC; Loquai C; Reinmuth N; Steins M; Zimmer L; Sendl A; Gutzmer R
Cancer Treat Rev; 2016 Apr; 45():7-18. PubMed ID: 26922661
[TBL] [Abstract][Full Text] [Related]
19. Management of Immunotherapy-Related Toxicities, Version 1.2019.
Thompson JA; Schneider BJ; Brahmer J; Andrews S; Armand P; Bhatia S; Budde LE; Costa L; Davies M; Dunnington D; Ernstoff MS; Frigault M; Hoffner B; Hoimes CJ; Lacouture M; Locke F; Lunning M; Mohindra NA; Naidoo J; Olszanski AJ; Oluwole O; Patel SP; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wahidi M; Wang Y; Johnson-Chilla A; Scavone JL
J Natl Compr Canc Netw; 2019 Mar; 17(3):255-289. PubMed ID: 30865922
[TBL] [Abstract][Full Text] [Related]
20. Management of immunotherapy toxicities in older adults.
Bhandari S; Gill AS; Perez CA; Jain D
Semin Oncol; 2018 Aug; 45(4):226-231. PubMed ID: 30446167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
